Torrent Pharmaceuticals Limited — PPTs, 30-06-2025: Investor Presentation

1. Financial Highlights:

Torrent Pharmaceuticals is acquiring a 46.39% stake in JB Chemicals & Pharmaceuticals for INR 11,917 Cr, implying significant capital deployment. JB Pharma reported FY25 revenues of INR 3,918 Cr with a CAGR of 18% over recent years. The business mix is balanced with 58% from India, 29% from international markets, 11% from CDMO, and 2% API. International revenues stood at INR 1,651 Cr, contributing 42% of JB Pharma’s total revenue. JB Pharma has shown consistent market outperformance and strong growth in high-value therapeutic segments like cardiology and gastroenterology.

2. Strategic Initiatives & Growth Drivers:

The merger expands Torrent’s presence into fast-growing therapeutic areas, deepening portfolio strength and brand equity. JB Pharma's dedicated capex of INR 450 Cr (FY21–25) focused on manufacturing and global regulatory accreditations (US FDA, EU GMP etc.) enhances operational capacity. The combined entity benefits from growth in emerging therapies such as pediatric dermatology, cardiac, ophthalmology, and gastroenterology, with JB Pharma’s leadership in chronic therapies and CDMO segments adding growth momentum.

3. Business Developments:

Post acquisition, Torrent will merge with JB Pharma, with the share swap ratio fixed at 51 Torrent shares for every 100 JB Pharma shares. This transaction enables integration of JB Pharma’s 8 manufacturing plants across Gujarat and supplements Torrent’s existing capabilities. JB Pharma’s global footprint spans 40+ countries with significant presence in South Africa, Russia, and emerging markets, plus robust US FDA approved facilities.

4. Market Position & Competitive Advantage:

The merger positions the combined entity as a top-5 player in several therapeutic areas, boosting market share and prescription rankings. JB Pharma holds strong differentiated niches such as being a top-5 global CDMO for lozenges and having several brands in the IPM top 300 with leadership in cardiology. Their scale, strong product portfolio, and extensive regulatory compliance form a solid competitive moat.

5. Investor Implications:

The acquisition and merger create a stronger, diversified pharma platform with enhanced growth potential in high-demand therapies and global markets. Investors should note positive growth drivers from portfolio diversification, operational synergies, and scale advantages. The timeline for completion of the merger is 15-18 months, with execution risks linked to approvals and integration processes to monitor. Overall, this move signals sustainable value creation prospects for shareholders.